New SCHWIND LASIK platform going strong at 6 months

Article

Six-month data for myopia treatments with the SCHWIND AMARIS laser show that it is effective and patient friendly.

Six-month data for myopia treatments with the SCHWIND AMARIS laser show that it is effective and patient friendly.

The multi-centric LASIK myopia study, conducted by Maria-Clara Arbelaez and colleagues, enrolled 358 eyes. Of all the eyes, 65% achieved a postoperative uncorrected visual acuity (UCVA) of 20/16 or better and 98% achieved a UCVA of 20/20 or better. Target refraction was also found to be good, with 96% of treated eyes falling into the ±0.5 D range.

Aberration-free treatments were also found to be very safe. More than 55% of eyes gained one or more lines of visual acuity after six months and the induction of higher order aberrations, compared with non-aspheric treatment, was minimal. The total RMS of postoperative higher order aberrations (for 6 mm analysis diameter) rose by an average of just 0.07 µm. This also resulted in higher contrast sensitivity for patients.

Importantly, good results were seen very shortly after treatment, with study participants attaining the same visual acuity as the preoperative best corrected vision just one day after the procedure.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.